

## Rapid Report

Open Access

# Toxic effects of drugs used to treat COVID-19 on *Artemia salina*

Denis Moledo de Souza Abessa<sup>1,2\*</sup> and Maysa Ueda de Carvalho<sup>1</sup>

Received: 6 January 2026

Revised: 1 April 2026

Accepted: 10 April 2026

Published online: 27 April 2026

## Abstract


During the COVID-19 pandemic, several drugs were extensively used to treat and prevent infections worldwide, increasing their release into the aquatic environment. However, the effects of COVID-19 drugs on marine organisms are poorly understood; therefore, studies on this topic are required. This study aimed to evaluate the acute toxicity of hydroxychloroquine, ivermectin, nitazoxanide, loratadine, and betamethasone in nauplii of the brine shrimp *Artemia salina*. Acute toxicity tests were conducted following established protocols for this species (NBR 16530) for 48 h of exposure, using a range of test concentrations for each substance, defined according to reported environmental concentrations or toxicity for other species. Hydroxychloroquine was not toxic at the tested concentrations; thus this drug does not pose a risk to *A. salina*. The other drugs caused significant mortality in brine shrimps. The lowest observed effect concentrations (LOECs) were as follows: Ivermectin, 1.0 µg/L; nitazoxanide, 0.05 mg/L; betamethasone, 4 µg/L; loratadine, 0.02 mg/L. The toxicity of the tested drugs to *A. salina* was ranked as ivermectin > betamethasone > loratadine > nitazoxanide > hydroxychloroquine. Further studies with marine species are necessary to determine the environmental risks posed by the drugs tested in this study.

**Keywords:** Marine ecotoxicology, COVID-19 drugs, Hydroxychloroquine, Ivermectin, Betamethasone, Loratadine, Nitazoxanide

## Highlights

- The acute toxicity of four drugs used to treat COVID-19 to *Artemia salina* nauplii was tested.
- The respective LOECs were 1.0 µg/L (ivermectin), 0.05 mg/L (nitazoxanide), 4 µg/L (betamethasone), and 0.02 mg/L (loratadine).
- Toxicities were ranked as ivermectin > betamethasone > loratadine > nitazoxanide > hydroxychloroquine.

## Graphical abstract



\* Correspondence: Denis Moledo de Souza Abessa ([denis.abessa@unesp.br](mailto:denis.abessa@unesp.br))

Full list of author information is available at the end of the article.

## Introduction

Pharmaceuticals and personal care products (PPCPs) are a large group of chemical substances that are used in medicine, healthcare, and personal hygiene and have been recognized as contaminants of emerging concern<sup>[1]</sup>. They have been detected in both tap water and several environmental matrices, such as soil, surface waters, groundwater, sediments, and the atmosphere<sup>[1]</sup>, as a result of inappropriate disposal of industrial and domestic effluents in the environment and irregular disposal of garbage, which leads to leaching into the soil and groundwater. In coastal zones, PPCPs in environmental matrices are primarily associated with the disposal of both treated and untreated sewage through submarine outfalls<sup>[2,3]</sup> and the direct discharge of stormwater. These chemicals have been reported in coastal waters worldwide, such as Costa Rica<sup>[4]</sup>, Taiwan<sup>[5]</sup>, Singapore<sup>[6]</sup>, Malaysia<sup>[7]</sup>, Sri Lanka<sup>[8]</sup>, and Brazil<sup>[9,10]</sup>. Moreover, because of their continuous usage and release into the environment, most PPCPs tend to occur at high concentrations, despite their half-lives, degradation rates, or dilution. Therefore, PPCPs have been considered to be pseudo-persistent contaminants<sup>[3]</sup>. Thus, in recent years, there has been increasing concern about the potential environmental risks that PPCPs may pose on aquatic biota and people living in coastal areas, especially in metropolitan zones and densely occupied areas<sup>[3]</sup>.

In December 2019, the COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), allegedly started in China and rapidly spread around the world. Because of the lack of vaccines against COVID-19, the rapid dissemination of the virus, and its severe impacts on human health, many drugs were used by the public in attempts to prevent or treat COVID-19<sup>[11,12]</sup>. These drugs include pharmaceuticals recommended by health authorities such as the World Health Organization (WHO) and the US Center for Disease Control and Prevention (CDC)<sup>[13]</sup>, as was the case of loratadine and betamethasone, and those that became popular through misinformation or political narratives, such as chloroquine, hydroxychloroquine, and ivermectin<sup>[14]</sup>, which were widely used, particularly in Brazil, India, and the USA<sup>[14–17]</sup>. For example, in Brazil, the sales of these drugs increased by more than 50% compared with 2019<sup>[14]</sup>. Various authors also stated that because of the inefficiency of municipal sanitation systems, particularly sewage collection and treatment, the release of these pharmaceuticals increased, along with their concentrations in the environment.

Loratadine is a second-generation antihistaminic drug used to treat allergies and inflammation<sup>[18]</sup>; it is not fully eliminated by conventional wastewater treatments and is found in aquatic environments at concentrations up to 81 ng/L<sup>[19]</sup>. Betamethasone is a synthetic glucocorticosteroid that mimics the action of cortisol, which is prescribed as an anti-inflammatory drug<sup>[20]</sup>, similar to dexamethasone. Glucocorticosteroids have been associated with adverse effects in aquatic organisms<sup>[21–25]</sup> at environmental concentrations<sup>[26]</sup>, including endocrine disruption in fish<sup>[20]</sup>. Hydroxychloroquine is a by-product derived from chloroquine (CQ)<sup>[27]</sup>, and both are used to treat malaria and rheumatic and dermatologic disorders of autoimmune origin<sup>[28,29]</sup>. Information on the toxicity of hydroxychloroquine in aquatic organisms is limited, but there is evidence that it is toxic to freshwater<sup>[30]</sup> and marine<sup>[31]</sup> organisms. Nitazoxanide is a broad-spectrum drug used to treat a wide range of parasites<sup>[32]</sup>. It is an inhibitor of pyruvate/ferrodoxin oxidoreductases, preventing the binding of pyruvate with thiamine pyrophosphate, which is a critical step in the anaerobic metabolism of protozoa<sup>[32]</sup>. This compound inhibits the growth of the microalgae *Euglena gracilis*<sup>[33]</sup> and causes adverse effects in zebrafish (*Dania rerio*) embryos<sup>[34]</sup>. However, there is no information regarding its

toxicity to marine organisms. Ivermectin is an antihelminthic drug that is widely used and is considered very toxic to a range of aquatic organisms<sup>[35–43]</sup>; however, its effects on marine organisms are still poorly understood. The existing literature regarding the environmental distribution of these substances and their toxicity to aquatic organisms is limited<sup>[18–43]</sup>, despite the widespread use of these drugs. Thus, studies on their effects on aquatic life have become crucial for understanding their environmental impact and should be prioritized<sup>[14]</sup>. In this study, we analyzed the effects of five drugs widely used during the COVID-19 pandemic on the brine shrimp *Artemia salina*, providing information to understand how the pandemic could have affected coastal ecosystems.

## Materials and methods

Five compounds were selected for assessment in this investigation, which used high-purity substances purchased from their respective manufacturers: loratadine (CAS #79794-75-5; molecular formula, C<sub>22</sub>H<sub>23</sub>ClN<sub>2</sub>O<sub>2</sub>; Sigma-Aldrich), betamethasone (CAS #378-44-9; molecular formula, C<sub>22</sub>H<sub>29</sub>FO<sub>5</sub>; Chemical Synthesis), hydroxychloroquine (CAS #118-42-3; molecular formula, C<sub>18</sub>H<sub>26</sub>ClN<sub>3</sub>O; Sigma-Aldrich), ivermectin (CAS #70288-86-7; molecular formula, C<sub>48</sub>H<sub>74</sub>O<sub>14</sub>; Chemical Synthesis), and nitazoxanide (CAS #55981-09-4; molecular formula, C<sub>12</sub>H<sub>9</sub>N<sub>3</sub>O<sub>5</sub>S). Loratadine and betamethasone have been recommended by health authorities<sup>[13]</sup> and are used to treat patients infected with COVID-19. In turn, hydroxychloroquine, ivermectin, and nitazoxanide were shown to be ineffective against COVID-19 but were still largely used in some countries because of widespread disinformation campaigns spread through social networks<sup>[14–17]</sup>.

The test concentrations for each substance were selected according to their reported environmental concentrations and the toxicities observed in freshwater organisms<sup>[17–43]</sup>. They were prepared by diluting the drugs, in powder form, in 1.0 mL of acetone and 99 mL of clean filtered seawater, followed by stirring until all the salts dissolved entirely and no precipitates could be observed in the solutions. The following nominal test solutions were prepared: 0.02, 0.2, 2, and 20 mg/L loratadine; 4, 40, 400, and 4,000 µg/L betamethasone; 0.1, 1, 10, and 100 mg/L hydroxychloroquine; 1, 10, 100, and 1,000 µg/L ivermectin; and 0.05, 0.5, 5, and 50 mg/L nitazoxanide. The control consisted of a 1% acetone solution prepared with clean filtered seawater. Previous data from our laboratory (unpublished data) showed that this concentration of acetone is not toxic to nauplii of *Artemia salina*, whereas the literature indicates that other marine organisms are not affected by acetone at this and lower concentrations<sup>[2,3,7,10]</sup>. Quality assurance/quality control (QA/QC) procedures during the toxicity tests consisted of using clean glassware, checking the physicochemical parameters of the test solutions, and using adequate controls. Moreover, the laboratory monitors the sensitivity of the test organism by conducting a toxicity test with a reference toxicant every month and comparing the results with a control chart.

Nauplii of *Artemia salina* were hatched from dehydrated cysts obtained commercially. Two days before the experiment, the cysts were introduced into a glass beaker containing 0.5 L of clean filtered seawater (salinity: 35‰) and kept under aeration at 25 °C. The nauplii hatched the following day, and after another 24 h, they were used in toxicity tests<sup>[44,45]</sup>. The acute toxicity test with *A. salina* nauplii was performed following the protocol described by ABNT NBR 16530<sup>[44]</sup>. The test was carried out using 15-mL glass test tubes as replicates, each containing 10 mL of the test solution at the abovementioned test concentrations. Four replicates were prepared for each concentration. Ten nauplii were selected and introduced

into each replicate using a dropper. At the beginning of the toxicity tests, pH, dissolved oxygen (DO), temperature, and salinity were measured for each test solution as well as for the control; temperature was also monitored every hour. The experiment consisted of exposing the organisms to the solutions for 48 h under controlled laboratory conditions (temperature  $25 \pm 2$  °C; photoperiod, 16:8 light : dark; lack of additional food). After 48 h, the organisms in each test tube were analyzed under a microscope and the survivors were counted.

The test results were initially checked for normality and variance homogeneity using Shapiro–Wilk and Levene's tests, respectively. Next, they were analyzed by one-way analysis of variance (ANOVA), followed by Dunnett's *t*-test, using a 95% significance level ( $p = 0.05$ ), in order to determine the lowest observed effect concentration (LOEC) and the no observed effect concentration (NOEC)<sup>[44,45]</sup>. The lethal concentration for 50% of organisms after 48 h of exposure (LC<sub>50-48 h</sub>) was calculated by the probit method, using Statistica 6.0 software.

## Results and discussion

The results of the toxicity tests are shown in Fig. 1 and Table 1. Figure 1 shows the survival rates of *A. salina* nauplii exposed to the tested pharmaceuticals, and the physicochemical parameters of the tested solutions are presented in Table 1. The physicochemical parameters were within the recommended ranges for all treatments, according to the test protocol for *A. salina*<sup>[44,45]</sup>. Thus, these factors did not interfere with the survival of the organisms.

Hydroxychloroquine showed no toxicity to *A. salina* nauplii at the tested concentrations. On the other hand, the other four compounds were toxic at all concentrations tested (Fig. 1, Table 2). The LC<sub>50-48 h</sub> of loratadine was 0.53 mg/L, whereas the LOEC was estimated at 0.02 mg/L. For betamethasone, the LOEC was 4 µg/L and the LC<sub>50-48 h</sub> was 33.64 µg/L (range: 22.25–50.86); for this compound, mortality was 100% at the highest tested concentration (4,000 µg/L). Regarding nitazoxanide, the LOEC was estimated as 0.05 mg/L, whereas the LC<sub>50-48 h</sub> was calculated as 0.64 mg/L (range: 0.21–1.93). Finally, the LOEC for ivermectin was estimated at 1 µg/L. The LC<sub>50-48 h</sub> could not be calculated, as mortality exceeded 50% at all tested concentrations.


The COVID-19 pandemic has affected populations worldwide, with more than 700 million people infected and > 7 million deaths<sup>[46]</sup>. Several pharmaceuticals have been proposed or used for treating COVID-19, initially reaching up to 700 to 1,000 potential drugs<sup>[47]</sup>. From this list, a smaller group remains, including drugs approved by health authorities, such as antibiotics, antiretroviral drugs, anti-inflammatory drugs, and analgesics. Additionally, drugs not officially recommended but widely used in some countries as a result of disinformation campaigns and generalized self-medication during lockdowns include veterinary medicines (e.g., ivermectin) and antimalarial drugs (e.g., hydroxychloroquine)<sup>[47,48]</sup>. For example, the increase in prescriptions and refills for hydroxychloroquine and chloroquine reported in the US in 2020 reached 1977%<sup>[49]</sup>. The consequence of this massive use of COVID-19-related drugs was an increase in the release of these substances or their by-products into the environment through wastewater treatment plants or direct discharge into water bodies<sup>[47,50,51]</sup>, similar to those observed for the environmental levels of Tamiflu during the H1N1 outbreak<sup>[52]</sup>. Therefore, assessing the toxicity of COVID-19 drugs to aquatic organisms is crucial for understanding their environmental impact and the broader consequences of the COVID-19 pandemic. This study provides new insights into the toxicity of five pharmaceuticals used

to treat COVID-19 in marine organisms during the SARS-CoV-2 pandemic.

Hydroxychloroquine did not cause toxicity to nauplii of *A. salina* at concentrations ranging between 0.1 and 100 mg/L, which are significantly higher than the environmental levels reported in the surface waters of Spain (32 ng/L)<sup>[48]</sup> and the predicted environmental concentration (78.3 ng/L)<sup>[48]</sup>. However, this range is similar to the concentrations reported in a wastewater treatment plant (0.11 mg/L) and river water (0.013–0.42 mg/L)<sup>[53]</sup>. Thus, according to our results and these environmental concentrations, acute toxicity to marine organisms would not be expected. However, Ramesh et al.<sup>[30]</sup> reported adverse biochemical effects in the fish *Cyprinus carpio* exposed to concentrations similar to those used in the present study. Information on hydroxychloroquine's toxicity to aquatic organisms is limited, and the existing results show varying responses. Zurita et al.<sup>[31]</sup> observed a lack of effects on the bacterium *Vibrio fischeri* and relevant toxicity to the cladoceran *Daphnia magna*, the fish *Poeciliopsis lucida*, and the microalgae *Chrorella vulgaris*. Moreover, the predicted no effect concentrations (PNECs) for this compound were 170 ng/L in river water<sup>[48]</sup>, with values ranging from 7.5 ng/L to 85 µg/L<sup>[54–56]</sup>. In another study on meiobenthic nematodes, hydroxychloroquine caused effects at low concentrations<sup>[57]</sup>. However, more information is needed on the toxicity of hydroxychloroquine in marine organisms. The lack of toxic effects on *A. salina*, compared with the toxicity reported in the literature, suggests that *A. salina* is more resistant to hydroxychloroquine. Hydroxychloroquine is expected to be relatively persistent, with a half-life of 138 days<sup>[58]</sup>, and its degradation products can be toxic<sup>[53]</sup>. However, more studies are necessary to determine the impact of hydroxychloroquine on marine organisms; in particular, studies focusing on chronic and subchronic effects are required.

This study is the first to investigate the toxicity of nitazoxanide to saltwater organisms. This antiparasite drug is widely used<sup>[32]</sup>, and previous studies have indicated its toxicity to microalgae<sup>[33]</sup> and zebrafish embryos<sup>[34]</sup>, and its effects involve the inhibition of the pyruvate : ferredoxin oxidoreductase (PFOR) enzyme-dependent electron transfer reactions necessary for anaerobic energy metabolism, inhibition of glutathione-S-transferase, and modulation of the glutamate-gated chloride ion channels<sup>[58,59]</sup>. In this study, nitazoxanide exhibited toxicity to *A. salina* at a concentration of 0.05 mg/L, with an LC<sub>50-48 h</sub> of 0.64 (0.21–1.93) mg/L. In a prospective study using ecological models<sup>[58]</sup>, this compound was considered very toxic to freshwater organisms, with an expected half-life of 12 days. According to a quantitative structure–activity relationship (QSAR) model, the predicted ecotoxicity values (pEC<sub>50</sub>) for *Pseudokirchneriella subcapitata*, *Daphnia magna*, *Oncorhynchus mykiss*, and *Pimephales promelas* were 8.61, 5.10, 4.64, and 5.60 mol/L, respectively<sup>[59]</sup>. This compound was capable of causing oxidative stress and immunotoxicity in zebrafish embryos at concentrations from 0.75 mg/L<sup>[34]</sup>. In *A. salina*, lethal toxicity occurred at lower concentrations, but the effects of nitazoxanide on marine organisms remain understudied, similar to hydroxychloroquine.

Among the drugs evaluated in this study, ivermectin has been the most extensively studied. It is a macrocyclic lactone used in both veterinary and human medicine as an antiparasitic drug<sup>[50]</sup>. Up to 90% of the drug is excreted by the body through the feces and urine<sup>[50]</sup>; thus, ivermectin can be released into water bodies through sewage, agricultural leachates, and urban drainage, especially in developing countries. Ivermectin is persistent in the environment<sup>[60]</sup>, with a half-life of over 100 days in marine sediments<sup>[61]</sup>. A previous study reported that approximately 31% of the initially applied ivermectin was transformed<sup>[62]</sup>. As a result, ivermectin concentrations were high in wastewater treatment plants<sup>[63]</sup>,



**Fig. 1** Mean survival rates of nauplii of *Artemia salina* exposed to COVID-19 drugs: (a) Hydroxychloroquine, (b) ivermectin, (c) nitazoxanide, (d) betamethasone, and (e) loratadine) for 48 h. The control treatment consists of a 1.0% acetone solution. Error bars indicate standard deviations.

and this compound was detected in rivers at levels ranging from 5 to 20 ng/L and in irrigation waters at 0.093 µg/L before the COVID-19 pandemic<sup>[50,52]</sup>.

According to Juarez et al.<sup>[64]</sup>, ivermectin acts as an agonist of several types of ligand-gated chloride ion channel receptors. It increases the activity of  $\gamma$ -aminobutyric acid (GABA) receptors or glutamate-gated chloride ion channels (Glu-Cl), which signal between the neurons and muscles in parasites, leading to both ionic impairment in cells and increased paralysis in invertebrates<sup>[63,64]</sup>, including crustaceans<sup>[65]</sup>. These findings are consistent with our results, in which ivermectin was highly toxic to *A. salina* nauplii, with an LOEC of 1 µg/L; moreover, mortalities were greater than 50% in all tested concentrations. In fact, ivermectin is considered to be highly toxic to freshwater organisms, such as microbes<sup>[36,41]</sup>, microalgae<sup>[36,39]</sup>, fish<sup>[36,38]</sup>, cladocerans<sup>[36,37,39,42]</sup>, and annelids<sup>[40]</sup>. Less information is available for marine organisms, but the existing data indicate high toxicity. A previous study reported acute toxicity in several marine organisms, with LC<sub>50</sub> values ranging between 0.026 (0.013–0.051) µg/L for the mysid *Neomysis integer* (48 h) and > 10,000 µg/L for *Hydrobia ulvae* (96 h) and nematodes<sup>[35]</sup>. Another study reported an LC<sub>50-96</sub> = 70 (44–96) ng/L for the mysid *Neomysis integer*<sup>[43]</sup>. The toxicities of ivermectin and other similar compounds

of the avermectin family were studied by Blizzard et al.<sup>[66]</sup>, who obtained an IC<sub>50</sub> of 870 µg/L for *A. salina*, which was much higher than the values reported in our study and those reported in the literature for other organisms<sup>[35,43]</sup>. In addition, the ecological models used to predict environmental risks of ivermectin suggest very high risks<sup>[63]</sup>, with toxic threshold levels ranging from 25 ng/L<sup>[37]</sup> to 1.5 µg/L<sup>[63]</sup>. Given its environmental concentrations and toxic thresholds, the environmental risks for ivermectin may occur along the coast of São Paulo.

There is limited information on the toxicity of loratadine and betamethasone to aquatic organisms, and data on their toxicity to marine organisms are lacking. In our study, loratadine caused adverse effects in *A. salina* at the lowest concentration tested (0.02 mg/L), with an LC<sub>50-48 h</sub> of 0.53 mg/L. If we compare our results with those obtained for freshwater organisms, *A. salina* was more sensitive than the water flea *Ceriodaphnia dubia* (LC<sub>50</sub> = 0.60 mg/L), the rotifer *Brachionus calyciflorus* (LC<sub>50</sub> = 17 mg/L), and the anostracan crustacean *Thamnocephalus platyurus* (LC<sub>50</sub> = 50.70 mg/L)<sup>[18]</sup>. Actually, the LC<sub>50</sub> obtained for *A. salina* was higher than the EC50 values obtained for *C. dubia* (28.14 µg/L) and *B. calyciflorus* (51.32 µg/L), and lower than that obtained for the microalgae *P. subcapitata* (2,155 µg/L)<sup>[18]</sup>. Moreover, the toxicity of loratadine to

**Table 1** Physicochemical parameter of the tested solutions in the toxicity tests with pharmaceuticals used to treat COVID-19

	Hydroxychloroquine (mg/L)					Nitazoxanide (mg/L)				Ivermectin (µg/L)				Loratadine (mg/L)				Betamethasone (µg/L)								
	Control	100	10	1	0.1	Control	50	5	0.5	0.05	Control	1,000	100	10	1	Control	20	2	0.2	0.02	Control	4,000	400	40	4	
Salinity	35	35	35	35	35	35	35	35	35	35	35	35	35	35	35	35	35	35	35	35	35	35	35	35	35	35
pH	8.1	7.9	7.9	8	8	8.2	7.7	7.7	7.9	7.9	8.2	7.7	7.9	8	8	8.1	8	8	8.1	8	8.1	8	8.1	8	8.1	8.1
Temperature (°C)	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25	25
D.O. (% saturation)	92	88	91	92	92	95	80	85	89	90	93	86	89	91	91	91	90	93	87	88	90	82	91	92	90	

**Table 2** Lethal concentrations to 50% of organisms (LC<sub>50-48 h</sub>) and the lowest observed effect concentrations (LOECs) obtained for nauplii of *Artemia salina* exposed to COVID-19 pharmaceuticals

Test compound	LC <sub>50-48 h</sub>	LOEC
Hydroxychloroquine	Not toxic	Not toxic
Ivermectin	NC	1.0 µg/L
Nitazoxanide	0.64 (0.21–1.93) mg/L	0.05 mg/L
Betamethasone	33.64 (22.25–50.86) µg/L	4.0 µg/L
Loratadine	0.53 mg/L	0.02 mg/L

*A. salina* was similar to that of the anti-histaminic compound promethazine hydrochloride<sup>[67]</sup>. The LOEC for *A. salina* is lower than the maximum concentration reported in surface waters<sup>[19]</sup>, suggesting potential environmental risks for loratadine. These risks may be aggravated by its degradation products, which can also be toxic<sup>[19]</sup> and are not fully removed by conventional wastewater treatments<sup>[19]</sup>.

Betamethasone was more toxic than loratadine, with an estimated LOEC of 4 µg/L and an LC<sub>50</sub> = 33.64 (22.25–50.86) µg/L. These toxic concentrations were higher than the environmental concentrations reported in rivers from the Czech Republic and Switzerland, which were in the range of 8–31 ng/L<sup>[68]</sup>. These were also higher than the PNEC proposed for endocrine disruption in freshwater fish<sup>[20,25,68]</sup>. Because little is known about the environmental levels and toxicity of betamethasone, we compared our results with those of dexamethasone, a parent compound that exhibits similar behavior. In this case, dexamethasone's environmental concentrations increased during and after the COVID-19 pandemic<sup>[26,50]</sup>, but its acute toxicity to freshwater organisms tended to be lower than that of betamethasone<sup>[21,22,59]</sup>. Estimations of the probable effect concentrations of dexamethasone were variable, with values ranging between 0.29 ng/L<sup>[48]</sup> and 0.003 mg/L<sup>[63]</sup>, which are also comparable with the LOEC estimated for betamethasone in the present study, yet the environmental risks were considered to be low by Tarazona et al.<sup>[63]</sup>.

## Conclusions

This study provides new information regarding the toxicity of nitazoxanide, hydroxychloroquine, ivermectin, loratadine, and betamethasone to an important aquatic euryhaline species, the brine shrimp *A. salina*. This species is globally distributed in lakes and coastal lagoons, and is abundant in hypersaline environments<sup>[69]</sup>. Most of these compounds caused toxicity in *A. salina* nauplii, except for hydroxychloroquine. The LC<sub>50</sub> values ranked the drugs' toxicity as ivermectin > betamethasone > nitazoxanide = loratadine > hydroxychloroquine, but this concentration could not be calculated for ivermectin and hydroxychloroquine. On the basis of their respective LOECs, which represent the toxic threshold, the toxicity of the tested drugs can be

ranked as follows: Ivermectin > betamethasone > loratadine > nitazoxanide > hydroxychloroquine. In this context, the increased use of these pharmaceuticals to treat or prevent COVID-19 likely contributed to higher levels of pharmaceuticals and personal care products in the environment.

More studies on these chemicals are necessary, particularly investigations aimed at detecting and quantifying COVID-19 drugs in marine environments<sup>[47]</sup>. Additionally, studies should focus on assessing their fate and behavior, bioavailability, bioaccumulation, toxicity, and environmental risks. In addition, effective strategies should be implemented to reduce or eliminate environmental contamination by COVID-19 drugs and their by-products. Such strategies involve improving sanitation systems by collecting domestic, hospital, and veterinary wastewater and adapting wastewater treatment plants to use a combination of advanced technologies for removing these drugs and other contaminants<sup>[47,50,52,63]</sup>. Some authors also recommend information campaigns aimed at avoiding the use of ineffective drugs by the population<sup>[63]</sup>, as was the case for ivermectin, hydroxychloroquine, and nitazoxanide. O'Flynn et al.<sup>[70]</sup> highlighted the life cycle assessment of pharmaceuticals from production to release into the aquatic environment, with the purpose of tracking the route of pharmaceuticals into the environment and following the sustainable development targets of SDG 6 (Clean Water and Sanitation), SDG 12 (Responsible Consumption and Production), and SDG 14 (Life Below Water).

## Author contributions

The authors confirm their contributions to the paper as follows: Denis Moledo de Souza Abessa: conceptualization, methodology, validation, formal analysis, investigation, resources, writing – original draft preparation, supervision, funding acquisition. Maysa Ueda de Carvalho: methodology, investigation, writing – review and editing. Both authors have read and agreed to the published version of the manuscript.

## Data availability

All data generated or analyzed during this study are included in this published article.

## Acknowledgments

We thank Drs. Guacira Pauly (UNESP) and Fernando Perina (University of Aveiro) for technical support. DMSA thanks Instituto Nacional de Identificação, Quantificação, Dispersão, Riscos Ambientais e Mitigação da Poluição por Contaminantes Emergentes em Ambientes Marinhos e Costeiros (INCT-CEMAR) for the financial support. We also dedicate this manuscript to all those people lost during the COVID-19 pandemic and those professionals who dedicated their efforts to save lives all around the world.

## Funding

This research was funded by the São Paulo Research Foundation (FAPESP) (Grant Nos. 2020/04779-6, 2022/09070-0, and 2025/27086-0), and the National Council for Scientific and Technological Development (CNPq) (Grant Nos. 308533/2018-6, 313420/2023-8, and 408782/2024-2).

## Declarations

### Competing interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

### Author details

<sup>1</sup>São Paulo State University, Biosciences Institute, São Vicente, SP 11330-900, Brazil; <sup>2</sup>Instituto Nacional de Identificação, Quantificação, Dispersão, Riscos Ambientais e Mitigação da Poluição por Contaminantes Emergentes em Ambientes Marinhos e Costeiros (INCT-CEMAR), São Vicente, SP 11330-900, Brazil

## References

- [1] Starling MCV, Amorim CC, Leão MMD. 2019. Occurrence, control and fate of contaminants of emerging concern in environmental compartments in Brazil. *Journal of Hazardous Materials* 372:17–36
- [2] Fontes MK, Gusso-Choueri PK, Maranhão LA, de Souza Abessa DM, Almeida Mazur W, et al. 2018. A tiered approach to assess effects of diclofenac on the brown mussel *Perna perna*: a contribution to characterize the hazard. *Water Research* 132:361–370
- [3] Maranhão LA, dos Santos DM, da Fonseca TG, dos Santos Barbosa Ortega A, da Silva Sousa L, et al. 2021. Occurrence and environmental fate of pharmaceuticals, personal care products and illicit drugs (PPCPIDs) in tropical ecosystems. In *Pharmaceuticals in Marine and Coastal Environments: Occurrence, Effects and Challenges in a Changing World*, eds. Durán-Álvarez JC, Jiménez-Cisneros B. Amsterdam: Elsevier. pp. 169–193 doi: [10.1016/B978-0-08-102971-8.00001-9](https://doi.org/10.1016/B978-0-08-102971-8.00001-9)
- [4] Sponberg AL, Witter JD, Acuña J, Vargas J, Murillo M, et al. 2011. Reconnaissance of selected PPCP compounds in Costa Rican surface waters. *Water Research* 45:6709–6717
- [5] Fang TH, Nan FH, Chin TS, Feng HM. 2021. The occurrence and distribution of pharmaceutical compounds in the effluents of a major sewage treatment plant in Northern Taiwan and the receiving coastal waters. *Marine Pollution Bulletin* 64:1435–1444
- [6] Bayen S, Zhang H, Desai MM, Ooi SK, Kelly BC. 2013. Occurrence and distribution of pharmaceutically active and endocrine disrupting compounds in Singapore's marine environment: influence of hydrodynamics and physical chemical properties. *Environmental Pollution* 182:1–8
- [7] Omar TFT, Aris AZ, Yusoff FM, Mustafa S. 2019. Risk assessment of pharmaceutically active compounds (PhACs) in the Klang River estuary, Malaysia. *Environmental Geochemistry and Health* 41:211–223
- [8] Guruge KS, Goswami P, Tanoue R, Nomiya K, Wijesekara RGS, et al. 2019. First nationwide investigation and environmental risk assessment of 72 pharmaceuticals and personal care products from Sri Lankan surface waterways. *Science of The Total Environment* 690:683–695
- [9] Beretta M, Britto V, Tavares TM, da Silva SMT, Pletsch AL. 2014. Occurrence of pharmaceutical and personal care products (PPCPs) in marine sediments in the Todos os Santos Bay and the north coast of Salvador, Bahia, Brazil. *Journal of Soils and Sediments* 14:1278–1286
- [10] Pereira CDS, Maranhão LA, Cortez FS, Pusceddu FH, Santos AR, et al. 2016. Occurrence of pharmaceuticals and cocaine in a Brazilian coastal zone. *Science of The Total Environment* 548:148–154
- [11] Moreira RDS. 2020. COVID-19: intensive care units, mechanical ventilators, and latent mortality profiles associated with case-fatality in Brazil. *Cadernos de Saúde Pública* 36(5):e00080020
- [12] Souza MNC, Ricardino IEF, Sampaio K, Silva MR, de Lima APG, et al. 2021. Occurrence of self-medication in the Brazilian population as a preventive strategy for SARS-CoV-2. *Research, Society and Development* 10(1):e44510111933
- [13] COVID-19 Treatment Guidelines Panel. 2019. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. [www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf\\_NBK570371.pdf](http://www.ncbi.nlm.nih.gov/books/NBK570371/pdf/Bookshelf_NBK570371.pdf)
- [14] Farias DF, Souza T, Souza JACR, Vieira LR, Muniz MS, et al. 2020. COVID-19 therapies in Brazil: should we be concerned with the impacts on aquatic wildlife? *Environmental Toxicology and Chemistry* 39(12):2348–2350
- [15] Goulart AH, Muñoz IK. 2020. Disinformation and post-truth in the context of the Covid-19 pandemic: a study of information practices on Facebook. *Liinc em Revista* 16(2):e5397
- [16] Tanni SE, Bacha HA, Naime A, Bernardo WM. 2021. Use of hydroxychloroquine to prevent SARS-CoV-2 infection and treat mild COVID-19: a systematic review and meta-analysis. *Jornal Brasileiro de Pneumologia* 47(5):e20210236
- [17] da Costa Gomes J, da Silva JCA, Batalha SSA. 2021. Occurrence of self-medication in the COVID-19 pandemic: an integrative literature review. *Research, Society and Development* 10(16):e308101624049
- [18] Ilesce MR, Lavorgna M, Russo C, Piscitelli C, Passananti M, et al. 2019. Ecotoxic effects of loratadine and its metabolic and light-induced derivatives. *Ecotoxicology and Environmental Safety* 170:664–672
- [19] Kristofco LA, Brooks BW. 2017. Global scanning of antihistamines in the environment: analysis of occurrence and hazards in aquatic systems. *Science of The Total Environment* 592:477–487
- [20] Vestel JS, Hong JY, Meng Q, Naumann BD, Robson MG, et al. 2017. The endocrine disruption potential of betamethasone using Japanese medaka as a fish model. *Human and Ecological Risk Assessment: An International Journal* 23(4):879–894
- [21] DellaGreca M, Fiorentino A, Isidori M, Lavorgna M, Previtiera L, et al. 2004. Toxicity of prednisolone, dexamethasone and their photochemical derivatives on aquatic organisms. *Chemosphere* 54(5):629–637
- [22] Bal N, Kumar A, Du J, Nugegoda D. 2017. Multigenerational effects of two glucocorticoids (prednisolone and dexamethasone) on life-history parameters of crustacean *Ceriodaphnia dubia* (Cladocera). *Environmental Pollution* 225:569–578
- [23] LaLone CA, Villeneuve DL, Olmstead AW, Medlock EK, Kahl MD, et al. 2012. Effects of a glucocorticoid receptor agonist, dexamethasone, on fathead minnow reproduction, growth, and development. *Environmental Toxicology and Chemistry* 31(3):611–622
- [24] Cuzziol Boccioni AP, Peltzer PM, Martinuzzi CS, Attademo AM, León EJ, et al. 2021. Morphological and histological abnormalities of the neotropical toad, *Rhinella arenarum* (Anura: Bufonidae) larvae exposed to dexamethasone. *Journal of Environmental Science and Health, Part B* 56(1):41–53
- [25] Kugathas S, Sumpter JP. 2011. Synthetic glucocorticoids in the environment: first results on their potential impacts on fish. *Environmental Science & Technology* 45:2377–2383
- [26] Domínguez-García P, Rodríguez RR, Barata C, Gómez-Canela C. 2023. Presence and toxicity of drugs used to treat SARS-CoV-2 in Llobregat River, Catalonia, Spain. *Environmental Science and Pollution Research* 30:49487–49497
- [27] Stokkermans TJ, Falkowitz DM, Trichonas G. 2025. *Chloroquine and Hydroxychloroquine Toxicity*. Treasure Island (FL): StatPearls Publishing. [www.ncbi.nlm.nih.gov/books/NBK537086/](http://www.ncbi.nlm.nih.gov/books/NBK537086/) (accessed on May 2, 2025)
- [28] Dabić D, Babić S, Škorić I. 2019. The role of the photodegradation in the environmental fate of hydroxychloroquine. *Chemosphere* 230:268–277
- [29] dos Reis Neto ET, Kakehasi AM, de Medeiros Pinheiro M, Ferreira GA, Marques CDL, et al. 2020. Revisiting hydroxychloroquine and chloroquine for patients with chronic immunity-mediated inflammatory rheumatic diseases. *Advances in Rheumatology* 60:32
- [30] Ramesh M, Anitha S, Poopal RK, Shobana C. 2018. Evaluation of acute and sublethal effects of chloroquine (C<sub>18</sub>H<sub>26</sub>ClN<sub>3</sub>) on certain enzymological and histopathological biomarker responses of a freshwater fish *Cyprinus carpio*. *Toxicology Reports* 5:18–27
- [31] Zurita JL, Jos Á, del Peso A, Salguero M, López-Artíguez M, et al. 2005. Ecotoxicological evaluation of the antimalarial drug chloroquine. *Aquatic Toxicology* 75:97–107

- [32] Arce-Fonseca M, Gutiérrez-Ocejo RA, Rosales-Encina JL, Aranda-Fraustro A, Cabrera-Mata JJ, et al. 2023. Nitazoxanide: a drug repositioning compound with potential use in Chagas disease in a murine model. *Pharmaceuticals* 16(6):826
- [33] Vignoles P, Dreyfuss G, Rondelaud D. 1996. Growth modification of *Euglena gracilis* Klebs after 2-benzamido-5-nitrothiazole derivatives application. *Ecotoxicology and Environmental Safety* 34(2):118–124
- [34] Lu W, Yang F, Meng Y, An J, Hu B, et al. 2023. Immunotoxicity and transcriptome analysis of zebrafish embryos exposure to nitazoxanide. *Fish & Shellfish Immunology* 141:108977
- [35] Grant A, Briggs AD. 1998. Toxicity of ivermectin to estuarine and marine invertebrates. *Marine Pollution Bulletin* 36(7):540–541
- [36] Halley BA, Jacob TA, Lu AYH. 1989. The environmental impact of the use of ivermectin: environmental effects and fate. *Chemosphere* 18(7–8):1543–1563
- [37] Sanderson H, Laird B, Pope L, Brain R, Wilson C, et al. 2007. Assessment of the environmental fate and effects of ivermectin in aquatic mesocosms. *Aquatic Toxicology* 85(4):229–240
- [38] Carlsson G, Patring J, Kreuger J, Norrgren L, Oskarsson A. 2013. Toxicity of 15 veterinary pharmaceuticals in zebrafish (*Danio rerio*) embryos. *Aquatic Toxicology* 126:30–41
- [39] Garric J, Vollat B, Duis K, Péry A, Junker T, et al. 2007. Effects of the parasiticide ivermectin on the cladoceran *Daphnia magna* and the green alga *Pseudokirchneriella subcapitata*. *Chemosphere* 69:903–910
- [40] Gerhardt A. 2009. Screening the toxicity of Ni, Cd, Cu, Ivermectin, and Imidacloprid in a short-term automated behavioral toxicity test with *Tubifex tubifex* (Müller 1774) (*Oligochaeta*). *Human and Ecological Risk Assessment* 15(1):27–40
- [41] Escher BI, Berger C, Bramaz N, Kwon JH, Richter M, et al. 2008. Membrane–water partitioning, membrane permeability, and baseline toxicity of the parasitides ivermectin, albendazole, and morantel. *Environmental Toxicology and Chemistry* 27(4):909–918
- [42] Lopes C, Charles S, Vollat B, Garric J. 2009. Toxicity of ivermectin on cladocerans: comparison of toxic effects on *Daphnia* and *Ceriodaphnia* species. *Environmental Toxicology and Chemistry* 28(10):2160–2166
- [43] Davies IM, McHenry JG, Rae GH. 1997. Environmental risk from dissolved ivermectin to marine organisms. *Aquaculture* 158:263–275
- [44] Associação Brasileira de Normas Técnicas (ABNT). 2016. Ecotoxicologia aquática - Toxicidade aguda - Método de ensaio com *Artemia* sp. (Crustacea, Brachiopoda) [Aquatic ecotoxicology - Acute toxicity - Test method with *Artemia* sp. (Crustacea, Brachiopoda)]. ABNT NBR 16530. ABNT, Rio de Janeiro, Brazil. [www.target.com.br/produtos/normas-tecnicas/44088/nbr16530-ecotoxicologia-aquatica-toxicidade-aguda-metodo-de-ensaio-com-artemia-sp-crustacea-brachiopoda](http://www.target.com.br/produtos/normas-tecnicas/44088/nbr16530-ecotoxicologia-aquatica-toxicidade-aguda-metodo-de-ensaio-com-artemia-sp-crustacea-brachiopoda) (accessed on April 9, 2026)
- [45] Veiga LF, Vital N. 2002. Teste de toxicidade aguda com o microcrustáceo *Artemia* sp. In *Métodos em Ecotoxicologia Marinha: Aplicações no Brasil*. eds. Nascimento IA, Souza ECPM, Nipper M. Vol. 1. São Paulo, SP, Brasil: Editora Artes Gráficas e Indústria Ltda. pp. 111–122
- [46] World Health Organization (WHO). 2025. WHO COVID-19 dashboard. <https://data.who.int/dashboards/covid19/cases> (accessed on May 7, 2025)
- [47] Gwenz W, Selvasembian R, Offiong NO, El Din Mahmoud A, Sanganyado E, et al. 2022. COVID-19 drugs in aquatic systems: a review. *Environmental Chemistry Letters* 20(2):1275–1294
- [48] Kuroda K, Li C, Dhangar K, Kumar M. 2021. Predicted occurrence, ecotoxicological risk and environmentally acquired resistance of antiviral drugs associated with COVID-19 in environmental waters. *Science of The Total Environment* 776:145740
- [49] Vaduganathan M, van Meijgaard J, Mehra MR, Joseph J, O'Donnell CJ, et al. 2020. Prescription fill patterns for commonly used drugs during the COVID-19 pandemic in the United States. *JAMA* 323:2524–2526
- [50] Nippes RP, Macruz PD, da Silva GN, Neves Olsen Scaliante MH. 2021. A critical review on environmental presence of pharmaceutical drugs tested for the covid-19 treatment. *Process Safety and Environmental Protection* 152:568–582
- [51] Chen WY, Lin CJ, Liao CM. 2014. Assessing exposure risks for aquatic organisms posed by Tamiflu use under seasonal influenza and pandemic conditions. *Environmental Pollution* 184:377–384
- [52] Morales-Paredes CA, Rodríguez-Díaz JM, Boluda-Botella N. 2022. Pharmaceutical compounds used in the COVID-19 pandemic: a review of their presence in water and treatment techniques for their elimination. *Science of The Total Environment* 814:152691
- [53] Kumar R, Sharma A, Srivastava JK, Siddiqui MH, Uddin MS, et al. 2021. Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications. *Environmental Science and Pollution Research* 28:40431–40444
- [54] Cappelli F, Longoni O, Rigato J, Rusconi M, Sala A, et al. 2022. Suspect screening of wastewaters to trace anti-COVID-19 drugs: potential adverse effects on aquatic environment. *Science of The Total Environment* 824:153756
- [55] Domingo-Echaburu S, Irazola M, Prieto A, Rocano B, Lopez de Torre-Queorejazu A, et al. 2022. Drugs used during the COVID-19 first wave in Vitoria-Gasteiz (Spain) and their presence in the environment. *Science of The Total Environment* 820:153122
- [56] Ferreira MT, dos Santos Carvalho C. 2023. Chloroquine and hydroxychloroquine in the environment and aquatic organisms: a review. *Ambiente e Agua – an Interdisciplinary Journal of Applied Science* 18:e2880
- [57] Ben Ali M, Hedfi A, Almalki M, Karachle PK, Boufahja F. 2021. Toxicity of hydroxychloroquine, a potential treatment for COVID-19, on free-living marine nematodes. *Marine Pollution Bulletin* 167:112361
- [58] Sanches-Neto FO, Coutinho ND, Aquilanti V, Silva WA, Carvalho-Silva VH. 2023. Mechanism and kinetics of the degradation of nitazoxanide and hydroxychloroquine drugs by hydroxyl radicals: theoretical approach to ecotoxicity. *Journal of the Brazilian Chemical Society* 34(8):1119–1129
- [59] Khan K, Kar S, Roy K. 2023. Are we ready to combat the ecotoxicity of COVID-19 pharmaceuticals? An *in silico* aquatic risk assessment. *Aquatic Toxicology* 256:106416
- [60] Löffler D, Römbke J, Meller M, Ternes TA. 2005. Environmental fate of pharmaceuticals in water/sediment systems. *Environmental Science & Technology* 39:5209–5218
- [61] Essid N, Allouche M, Lazzem M, Harrath AH, Mansour L, et al. 2020. Ecotoxic response of nematodes to ivermectin, a potential anti-COVID-19 drug treatment. *Marine Pollution Bulletin* 157:111375
- [62] Prasse C, Löffler D, Ternes TA. 2009. Environmental fate of the anthelmintic ivermectin in an aerobic sediment/water system. *Chemosphere* 77:1321–1325
- [63] Tarazona JV, Martínez M, Martínez MA, Anadón A. 2021. Environmental impact assessment of COVID-19 therapeutic solutions. A prospective analysis. *Science of The Total Environment* 778:146257
- [64] Juárez M, Schcolnik-Cabrera A, Dueñas-Gonzalez A. 2018. The multitargeted drug ivermectin: from an antiparasitic agent to a repositioned cancer drug. *American Journal of Cancer Research* 8:317–331
- [65] Martin RJ, Robertson AP, Choudhary S. 2021. Ivermectin: an anthelmintic, an insecticide, and much more. *Trends in Parasitology*, 37(1):48–64
- [66] Blizzard TA, Ruby CL, Mrozik H, Preiser FA, Fisher MH. 1989. Brine shrimp (*Artemia salina*) as a convenient bioassay for avermectin analogs. *The Journal of Antibiotics* 42(8):1304–1307
- [67] Ignoto S, Pecoraro R, Scalisi EM, Buttigè SE, Contino M, et al. 2022. Acute toxicity of a marine emerging pollutant (promethazine hydrochloride) on *Artemia* sp. *ACS Omega* 7(44):39619–39623
- [68] Macikova P, Groh KJ, Ammann AA, Schirmer K, Suter MJ. 2014. Endocrine disrupting compounds affecting corticosteroid signaling pathways in Czech and Swiss waters: potential impact on fish. *Environmental Science & Technology* 48:12902–12911
- [69] Zhang H, Sun J, Wang W, Yu J. 2011. Brine shrimp diversity in China based on DNA barcoding. In *Changing Diversity in Changing Environment*. eds. Grillo O, Venora G. London, UK: IntechOpen. pp. 243–258 doi: 10.5772/24975
- [70] O'Flynn D, Lawler J, Yusuf A, Parle-McDermott A, Harold D, et al. 2021. A review of pharmaceutical occurrence and pathways in the aquatic environment in the context of a changing climate and the COVID-19 pandemic. *Analytical Methods* 13:575–594



Copyright: © 2026 by the author(s). Published by Maximum Academic Press, Fayetteville, GA. This article is an open access article distributed under Creative Commons Attribution License (CC BY 4.0), visit <https://creativecommons.org/licenses/by/4.0>.